Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00929110




Registration number
NCT00929110
Ethics application status
Date submitted
25/06/2009
Date registered
26/06/2009
Date last updated
17/08/2012

Titles & IDs
Public title
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
Scientific title
A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease
Secondary ID [1] 0 0
2008-008394-63
Secondary ID [2] 0 0
CNVA237A2303
Universal Trial Number (UTN)
Trial acronym
GLOW2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Glycopyrronium bromide
Treatment: Drugs - Placebo to glycopyrronium bromide
Treatment: Drugs - Tiotropium

Experimental: Glycopyrronium bromide 50 µg - Patients inhaled glycopyrronium bromide 50 µg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Placebo Comparator: Placebo to glycopyrronium bromide - Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Active Comparator: Tiotropium 18 µg - Patients inhaled tiotropium 18 µg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.


Treatment: Drugs: Glycopyrronium bromide
Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.

Treatment: Drugs: Placebo to glycopyrronium bromide
Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.

Treatment: Drugs: Tiotropium
Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Transition Dyspnea Index (TDI) at Week 26
Timepoint [1] 0 0
Week 26
Secondary outcome [2] 0 0
Health-related Quality of Life (QoL) Assessed With the St. George Respiratory Questionnaire (SGRQ) at Week 52
Timepoint [2] 0 0
Week 52
Secondary outcome [3] 0 0
Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)
Timepoint [3] 0 0
Baseline to Week 52 (patients with no moderate or severe exacerbations who completed the study were censored at the final visit date, which may have exceeded 52 weeks)
Secondary outcome [4] 0 0
Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Taken During the Study (Baseline to Week 52)
Timepoint [4] 0 0
Baseline to Week 52
Secondary outcome [5] 0 0
Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1, Week 26, and Week 52
Timepoint [5] 0 0
Day 1, Week 26, and Week 52
Secondary outcome [6] 0 0
Trough Forced Vital Capacity (FVC) at Day 1, Week 12, Week 26, and Week 52
Timepoint [6] 0 0
Day 1, Week 12, Week 26, and Week 52
Secondary outcome [7] 0 0
Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Timepoint [7] 0 0
5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Secondary outcome [8] 0 0
Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Timepoint [8] 0 0
5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Secondary outcome [9] 0 0
Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post Dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Timepoint [9] 0 0
5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Secondary outcome [10] 0 0
Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Timepoint [10] 0 0
5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Secondary outcome [11] 0 0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at Day 1 and Weeks 12, 26, and 52
Timepoint [11] 0 0
From 5 minutes to 4 hours post-dose at Day 1 and Weeks 12, 26, and 52
Secondary outcome [12] 0 0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours Post-dose at Day 1 and Weeks 12 and 52
Timepoint [12] 0 0
From 5 minutes to 12 hours post-dose at Day 1 and Weeks 12 and 52
Secondary outcome [13] 0 0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes and From 12 Hours to 23 Hours 45 Minutes Post-dose at Weeks 12 and 52
Timepoint [13] 0 0
From 5 minutes to 23 hours 45 minutes post-dose at Weeks 12 and 52
Secondary outcome [14] 0 0
Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Per Year During the Study (Baseline to Week 52)
Timepoint [14] 0 0
Baseline to Week 52
Secondary outcome [15] 0 0
Percentage of Patients Who Experienced a Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)
Timepoint [15] 0 0
Baseline to Week 52
Secondary outcome [16] 0 0
Percentage of Nights With "no Nighttime Awakenings" During the Study (Baseline to Week 52)
Timepoint [16] 0 0
Baseline to Week 52
Secondary outcome [17] 0 0
Percentage of Days With "no Daytime Symptoms" During the Study (Baseline to Week 52)
Timepoint [17] 0 0
Baseline to Week 52
Secondary outcome [18] 0 0
Percentage of "Days Able to Perform Usual Daily Activities" During the Study (Baseline to Week 52)
Timepoint [18] 0 0
Baseline to Week 52
Secondary outcome [19] 0 0
Change From Baseline in the Mean Daily Total Symptom Score During the Study (Baseline to Week 52)
Timepoint [19] 0 0
Baseline to Week 52

Eligibility
Key inclusion criteria
1. Male or female adults aged = 40 years, who have signed an Informed Consent Form prior
to initiation of any study-related procedure.

2. Patients with moderate to severe stable chronic obstructive pulmonary disease (COPD,
Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) Guidelines 2008.

3. Current or ex-smokers who have a smoking history of at least 10 pack years.

4. Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) = 30%
and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity
(FVC) < 0.7 at Visit 2 (Day -14).

5. Patients, according to daily electronic diary data between Visit 2 (Day -14) and Visit
3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to
Visit 3 (Day 1).
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy
test).

2. Women of child-bearing potential, unless using an approved method of medical or
surgical contraception.

3. Patients requiring long term oxygen therapy (> 15 h a day) on a daily basis for
chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways
disease in the 6 weeks prior to Visit 1 (Day -21) or between Visit 1 (Day -21) and
Visit 3 (Day 1).

4. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1
(Day -21).

5. Patients who, in the judgment of the investigator or the responsible Novartis
personnel, have a clinically relevant laboratory abnormality or a clinically
significant condition.

6. Patients with any history of asthma indicated by (but not limited to) a blood
eosinophil count > 600/mm^3 (at Visit 1, Day -21) and onset of symptoms prior to age
40 years.

7. Patients with a history of long QT syndrome or whose QTc measured at Visit 1 (Day -21)
(Fridericia method) is prolonged (> 450 ms for males or > 470 ms for females.

Other protocol-defined inclusion/exclusion criteria may apply to the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2011
Sample size
Target
Accrual to date
Final
1066
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
Montana
Country [20] 0 0
United States of America
State/province [20] 0 0
Nebraska
Country [21] 0 0
United States of America
State/province [21] 0 0
New Jersey
Country [22] 0 0
United States of America
State/province [22] 0 0
New York
Country [23] 0 0
United States of America
State/province [23] 0 0
North Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Oregon
Country [27] 0 0
United States of America
State/province [27] 0 0
Pennsylvania
Country [28] 0 0
United States of America
State/province [28] 0 0
Rhode Island
Country [29] 0 0
United States of America
State/province [29] 0 0
South Carolina
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
Washington
Country [34] 0 0
United States of America
State/province [34] 0 0
Wisconsin
Country [35] 0 0
Argentina
State/province [35] 0 0
Buenos Aires
Country [36] 0 0
Argentina
State/province [36] 0 0
Capital Federal
Country [37] 0 0
Argentina
State/province [37] 0 0
La Plata - Bueno Aire
Country [38] 0 0
Argentina
State/province [38] 0 0
Parana Entre Rios
Country [39] 0 0
Argentina
State/province [39] 0 0
Rosario
Country [40] 0 0
Argentina
State/province [40] 0 0
Tucuman
Country [41] 0 0
Canada
State/province [41] 0 0
Brampton
Country [42] 0 0
Canada
State/province [42] 0 0
Calgary
Country [43] 0 0
Canada
State/province [43] 0 0
Edmonton
Country [44] 0 0
Canada
State/province [44] 0 0
Kelowna
Country [45] 0 0
Canada
State/province [45] 0 0
Langley
Country [46] 0 0
Canada
State/province [46] 0 0
Niagara Falls
Country [47] 0 0
Canada
State/province [47] 0 0
Quebec
Country [48] 0 0
Canada
State/province [48] 0 0
Ste-Foy
Country [49] 0 0
Chile
State/province [49] 0 0
Santiago
Country [50] 0 0
Chile
State/province [50] 0 0
Talcahuano
Country [51] 0 0
Chile
State/province [51] 0 0
Vina del Mar
Country [52] 0 0
France
State/province [52] 0 0
Dijon
Country [53] 0 0
France
State/province [53] 0 0
Paris
Country [54] 0 0
France
State/province [54] 0 0
Rennes Cedex
Country [55] 0 0
Germany
State/province [55] 0 0
Berlin
Country [56] 0 0
Germany
State/province [56] 0 0
Landsberg
Country [57] 0 0
Germany
State/province [57] 0 0
Muenchen
Country [58] 0 0
Germany
State/province [58] 0 0
Munich
Country [59] 0 0
Hungary
State/province [59] 0 0
Gyonsyos
Country [60] 0 0
Hungary
State/province [60] 0 0
Siokok
Country [61] 0 0
Israel
State/province [61] 0 0
Be'er Sheva
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Jerusalem
Country [64] 0 0
Israel
State/province [64] 0 0
Kfar Saba
Country [65] 0 0
Israel
State/province [65] 0 0
Rehovot
Country [66] 0 0
Italy
State/province [66] 0 0
Firenze
Country [67] 0 0
Italy
State/province [67] 0 0
Monza
Country [68] 0 0
Italy
State/province [68] 0 0
Parma
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Busan
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Gyeonggi-go
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Incheon
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Seoul
Country [73] 0 0
Mexico
State/province [73] 0 0
Guadalajara
Country [74] 0 0
Mexico
State/province [74] 0 0
Monterrey
Country [75] 0 0
Mexico
State/province [75] 0 0
San Luis Potosi
Country [76] 0 0
Netherlands
State/province [76] 0 0
Sneek
Country [77] 0 0
New Zealand
State/province [77] 0 0
Auckland
Country [78] 0 0
New Zealand
State/province [78] 0 0
Christchurch
Country [79] 0 0
New Zealand
State/province [79] 0 0
Hamilton
Country [80] 0 0
New Zealand
State/province [80] 0 0
Tauranga
Country [81] 0 0
New Zealand
State/province [81] 0 0
Wellington
Country [82] 0 0
Peru
State/province [82] 0 0
Lima
Country [83] 0 0
Peru
State/province [83] 0 0
Santiago de Surco
Country [84] 0 0
Poland
State/province [84] 0 0
Bialystok
Country [85] 0 0
Poland
State/province [85] 0 0
Bydgoszcz
Country [86] 0 0
Poland
State/province [86] 0 0
Bystra
Country [87] 0 0
Poland
State/province [87] 0 0
Gdansk
Country [88] 0 0
Poland
State/province [88] 0 0
Krakow
Country [89] 0 0
Poland
State/province [89] 0 0
Ostrow Wielkopolski
Country [90] 0 0
Poland
State/province [90] 0 0
Piekary Slaskic
Country [91] 0 0
Poland
State/province [91] 0 0
Tarnow
Country [92] 0 0
Poland
State/province [92] 0 0
Warszawa
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Barnaul
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Irkutsk
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Moscow
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Smolensk
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Volgograd
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Yaroslavl

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily
(od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic
obstructive pulmonary disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00929110
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries